Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
GlaxoSmithKline and Theravance have secured marketing authorization from the European Commission for Anoro (umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
The drug is a combination of umeclidinium(UMEC), a long-acting muscarinic antagonist (LAMA) that helps lung function, and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single inhaler, the Ellipta.
The company said that the licensed strength of UMEC/VI in Europe is 55mcg / 22mcg.
GSK SVP and head of Global Respiratory Franchise Darrell Baker said there are many people across Europe living with COPD who experience a variety of symptoms and for whom the disease represents a significant burden.
http://drugdelivery.pharmaceutical-...-for-copd-drug-anoro-in-europe-090514-4263874
The drug is a combination of umeclidinium(UMEC), a long-acting muscarinic antagonist (LAMA) that helps lung function, and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single inhaler, the Ellipta.
The company said that the licensed strength of UMEC/VI in Europe is 55mcg / 22mcg.
GSK SVP and head of Global Respiratory Franchise Darrell Baker said there are many people across Europe living with COPD who experience a variety of symptoms and for whom the disease represents a significant burden.
http://drugdelivery.pharmaceutical-...-for-copd-drug-anoro-in-europe-090514-4263874